Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin LymphomaПодробнее

Christopher Yasenchak, MD, on 1st line brentuximab vedotin + nivolumab in Hodgkin’s lymphomaПодробнее

Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphomaПодробнее

Improving safety and efficacy with brentuximab vedotin, nivolumab and AD for advanced stage cHL.Подробнее

Alex Herrera on Nivolumab/Brentuximab Vedotin Combination for Patients with Hodgkin LymphomaПодробнее

Brentuximab vedotin + nivolumab in lymphomaПодробнее

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphomaПодробнее

Acceptable Safety Observed With Frontline Brentuximab Vedotin Combo in HLПодробнее

SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HLПодробнее

SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphomaПодробнее

Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trialПодробнее

E4412 update: ipi-nivo-brentuximab for R/R Hodgkin lymphomaПодробнее

The Impact of CheckMate-205 for Patients With Classical Hodgkin LymphomaПодробнее

Novel agents for the treatment of Hodgkin lymphoma: brentuximab vedotin and nivolumabПодробнее

Lymphoma updates: CAR-T, brentuximab & nivolumabПодробнее

Brentuximab vedotin combined with nivolumab for Hodgkin lymphomaПодробнее

Results of SWOG S1826 Study, showing Nivo-AVD better than BV-AVD in Hodgkin's Lymphoma patientsПодробнее

Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCLПодробнее

Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin LymphomaПодробнее